Dose escalation part: to determine the highest dose of BYL719 administered on a daily basis when given in combination with daily Everolimus or in combination with daily Everolimus and Exemestane.

Dose expansion part: To describe safety and tolerability of the BYL719 and Everolimus or BYL719, Everolimus and Exemestane combinations. To explore preliminary signs of efficacy of BYL719 and everolimus, and of the triplet combination (BYL719, everolimus, and exemestane) in selected patient populations by cohort

To determine the MTD and/or RDE of BYL719 in combination with everolimus, and the MTD and/or RDE of BYL719 in combination with everolimus and exemestane.

A dose-limiting toxicity (DLT) is an adverse event or abnormal laboratory value assessed as being unrelated to disease, disease progression, inter-current illness, or concomitant medications, and that occurs within the first 35 days of treatment with BYL719 plus Everolimus or BYL719 plus Everolimus plus Exemestane and meets any of the pre-defined criteria.

Dose expansion: Number of patients with adverse events as a measure of safety and tolerability [ Time Frame: Screening, every 28 days until 30 days after last dose ] [ Designated as safety issue: Yes ]

Type, intensity, severity and seriousness of adverse events according to the National Cancer Institute Common Terminology Criteria for Advers Events (NCI CTC AE) v4.03. Dose interruptions, reductions and dose intensity

Secondary Outcome Measures:

Dose escalation: Number of patients with adverse events as a measure of safety and tolerability [ Time Frame: Screening, every 28 days, until 30 days after last dose ] [ Designated as safety issue: Yes ]

Dose expansion: Progression free survival [ Time Frame: Baseline, every 8 weeks from start of treatment until first documented disease progression up to 2.5 years. ] [ Designated as safety issue: No ]

Progression-free survival is defined as the time from start date of study treatment until objective tumor progression or death from any cause.

Dose expansion : Duration of Response [ Time Frame: Baseline, every 8 weeks from start of treatment until first documented disease progressionup to 2.5 years. ] [ Designated as safety issue: No ]

Duration of response is defined as the time of first occurrence of Complete Response or Partial Response until the date of the first documented disease progression or death due to the disease.

Dose expansion: Clinical benefit Rate [ Time Frame: Baseline, every 8 weeks from start of treatment until first documented disease progression up to 2.5 years. ] [ Designated as safety issue: No ]

Clinical benefit rate is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) or stable disease (SD) for more than 24 weeks of duration of response.

Dose expansion: Overall response rate [ Time Frame: Baseline, every 8 weeks from start of treatment until first documented disease progression up to 2.5 years. ] [ Designated as safety issue: No ]

Overall response rate is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR), based on RECIST 1.1 criteria and the investigator assessment.

BYL719 will be administered orally once daily on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 8 of Cycle 1 in the dose escalation part and Day 1 of Cycle 1 in the dose expansion part. In the dose escalation part, the BYL719 starting dose will be 250 mg, with anticipated dose escalation to 350mg. In the dose expansion part, BYL719 will be administered at the recommended dose determined in the dose escalation part.

Drug: Everolimus

Everolimus will be administered orally once daily on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 1 of cycle 1 in both the dose escalation and dose expansion parts. In the dose escalation part, the Everolimus starting dose will be 2,5 mg, with anticipated dose escalation to 10 mg. In the dose expansion part, Everolimus will be administered at the recommended dose determined in the dose escalation part.

Experimental: BYL719, Everolimus and Exemestane

BYL719, Everolimus and Exemestane administered once a day

Drug: BYL719

BYL719 will be administered orally once daily on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 8 of Cycle 1 in the dose escalation part and Day 1 of Cycle 1 in the dose expansion part. In the dose escalation part, the BYL719 starting dose will be 250 mg, with anticipated dose escalation to 350mg. In the dose expansion part, BYL719 will be administered at the recommended dose determined in the dose escalation part.

Drug: Everolimus

Everolimus will be administered orally once daily on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 1 of cycle 1 in both the dose escalation and dose expansion parts. In the dose escalation part, the Everolimus starting dose will be 2,5 mg, with anticipated dose escalation to 10 mg. In the dose expansion part, Everolimus will be administered at the recommended dose determined in the dose escalation part.

Drug: Exemestane

Exemestane will be administered orally once daily on a continuous dose of 25 mg starting on Day 1 of Cycle 1 in both the dose escalation and dose expansion parts.

Eligibility

Ages Eligible for Study:

18 Years and older

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria For entire trial:

Adult > or = 18 years old

has signed the Informed Consent Form

has tumor tissue available for the analysis as described in the protocol

has an Eastern Cooperative Oncology Group performance status ≤2

has adequate bone marrow and organ function as defined in the protocol

is able to swallow and retain oral medication

has either measurable or non-measurable disease as per RECIST 1.1. Inclusion Criteria for the BYL719+ Everolimus combination - escalation phase

all of above first 7 criteria plus has an histologically/cytologically confirmed pancreatic NeuroEndocrine Tumor as detailed in the protocol Inclusion Criteria for the BYL719+ Everolimus combination - expansion phase, mTOR inhibitor-pretreated patients' cohort

all of above first 7 criteria plus has a histologically and/or cytologically confirmed solid malignancy as described in the protocol Inclusion Criteria for the BYL719+ Everolimus+Exemestane combination - escalation and expansion phases, breast cancer cohort

all of above first 7 criteria plus is post-menopausal and has a histologically and/or cytologically confirmed diagnosis of breast cancer as described in the protocol

Patient has a history of another malignancy within 2 years prior to starting study treatment as described in the protocol

Patient who has not recovered to grade 1 or better (except alopecia) from related side effects of any prior antineoplastic therapy

Patient who has had systemic therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study entry

Patient who has received radiotherapy ≤ 4 weeks prior to starting study drugs, with exception of palliative radiotherapy (≤ 2 weeks prior to starting study drugs), who has not recovered from side effects of such therapy to baseline or Grade ≤ 1 and/or from whom ≥ 30% of the bone marrow was irradiated

Patient who has undergone major surgery ≤ 4 weeks prior to starting study treatment or who has not recovered from side effects of such procedure

Patient has a clinically significant cardiac disease or impaired cardiac function or any severe and/or uncontrolled medical conditions as detailed in the protocol

Patient who is currently receiving medication with a known risk of prolonging the QT interval or inducing Torsades de Pointes (TdP) and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug treatment

Patient who has participated in a prior investigational study within 30 days prior to enrollment

Patient who is currently receiving treatment with drugs known to be moderate or strong inhibitors or inducers of isoenzymes CYP34A or CYP2C8 as described in the protocol. Switching to a different medication prior to start of treatment is allowed

Patient with impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral BYL719, everolimus, exemestane

Patient with known positive serology for human immunodeficiency virus

Patients who have received live attenuated vaccines within 1 week of start of study drug and during the study. Patient should also avoid close contact with others who have received live attenuated vaccines

Pregnant or nursing (lactating) woman as detailed in the protocol.

Patient who does not apply highly effective contraception during the study and through the duration as defined in the protocol

Patients in the mTOR inhibitor-pretreated cohorts: all of above first 18 criteria plus have discontinued prior mTOR inhibitor therapy due to non-tolerable toxicity

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02077933